Search

PRX-P4-003

PRX-P4-003 is under investigation in clinical trial NCT04638803 (A Phase 0, Open-Label, Crossover Microdose Pharmacokinetic Study of PRX-P4-003 in Healthy Volunteers). … PRX-P4-003 is a small molecule drug.

Flibanserin

in the brain as well as an effect on increasing norepinephrine and dopamine neurotransmitters. … It was originally developed as an antidepressant medication by Boehringer Ingelheim, but showed lack of efficacy in trials and was further developed as a hypoactive sexual disorder drug by Sprout Pharmaceuticals

Deucravacitinib

[L43150] It was later approved by Health Canada in November 2022 [L44216] and by the European Medicines Agency in March 2023.[L45788] … Deucravacitinib is a novel oral selective tyrosine kinase 2 (TYK2) inhibitor.

Tetraferric tricitrate decahydrate

Tetraferric tricitrate decahydrate is an iron containing phosphate binder used to treat hyperphosphatemia and iron deficiency anemia in adults with chronic kidney disease.

Celecoxib

[A181544] It is used to manage symptoms of various types of arthritis pain and in familial adenomatous polyposis (FAP) to reduce precancerous polyps in the colon. … [A181532] It is marketed by Pfizer under the brand name Celebrex, and was initially granted FDA approval in 1998.

Gadoteridol

gadolinium in the brain. … [A263076] Initially approved by the FDA in 1992, gadoteridol received additional approval in 2020 for use in pediatric patients less than 2 years old.[L49876]

Salmeterol

[A190459] Salmeterol was first described in the literature in 1988.[A190477] Salmeterol's structure is similar to salbutamol's with an aralkyloxy-alkyl substitution on the amine. … Salmeterol is a long-acting beta-2 adrenergic receptor agonist drug that is currently prescribed for the treatment of asthma and chronic obstructive pulmonary disease COPD.

Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated)